0.72
+0.0174(+2.48%)
Currency In USD
| Previous Close | 0.7 |
| Open | 0.72 |
| Day High | 0.73 |
| Day Low | 0.69 |
| 52-Week High | 7.5 |
| 52-Week Low | 0.65 |
| Volume | 68,197 |
| Average Volume | 412,095 |
| Market Cap | 5.36M |
| PE | -0.07 |
| EPS | -10.6 |
| Moving Average 50 Days | 0.74 |
| Moving Average 200 Days | 1.69 |
| Change | 0.02 |
If you invested $1000 in Pasithea Therapeutics Corp. (KTTA) since IPO date, it would be worth $9.82 as of August 18, 2025 at a share price of $0.699. Whereas If you bought $1000 worth of Pasithea Therapeutics Corp. (KTTA) shares 3 years ago, it would be worth $26.68 as of August 18, 2025 at a share price of $0.699.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients
GlobeNewswire Inc.
Jul 31, 2025 11:01 AM GMT
– Initial interim safety, tolerability, biomarker, and preliminary efficacy data expected in Q1 2026 –MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology
Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board
GlobeNewswire Inc.
Jun 11, 2025 11:02 AM GMT
Dr. James Lee of the Francis Crick Institute will help guide development of PAS-004 for ETS2-driven diseases such as inflammatory bowel disease (IBD)MIAMI, June 11, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or
Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025
GlobeNewswire Inc.
Jun 02, 2025 12:02 PM GMT
-- PAS-004 demonstrates preliminary clinical activity as a monotherapy in patients with heavily pre-treated, refractory solid tumors -- -- One patient in cohort 4A (15mg capsule) with stage 4 BRAF-mutated melanoma, who had progressed after two prior